Triple versus dual inhaler therapy in moderate‐to‐severe COPD: A systematic review and meta‐analysis of randomized controlled trials

Y Zayed, M Barbarawi, B Kheiri… - The clinical …, 2019 - Wiley Online Library
Introduction Treatment of chronic obstructive pulmonary disease (COPD) is evolving
specially with triple inhaler therapy. Objectives To perform a meta‐analysis to ascertain the …

The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a …

CC Lai, CH Chen, CYH Lin, CY Wang… - International journal of …, 2019 - Taylor & Francis
Background This study aims to compare the effects of single inhaler triple therapy comprised
of inhaled corticosteroids (ICSs), long-acting β2-agonists (LABAs), and long-acting …

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses

DMG Halpin, R Birk, N Brealey, GJ Criner… - ERJ open …, 2018 - Eur Respiratory Soc
Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-
agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive …

Triple therapy in COPD: what we know and what we don't

PMA Calverley, H Magnussen… - COPD: Journal of …, 2017 - Taylor & Francis
Triple inhaled therapy for chronic obstructive pulmonary disease (COPD) consists of an
inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA) and a long-acting muscarinic …

Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis

M Cazzola, P Rogliani, L Calzetta… - European Respiratory …, 2018 - Eur Respiratory Soc
We performed a meta-analysis to compare the impact of triple combination therapy with
inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs) and long-acting muscarinic …

Triple therapy versus dual bronchodilation and inhaled corticosteroids/long-acting β-agonists in COPD: accumulating evidence from network meta-analyses

M Cazzola, L Calzetta, P Rogliani, MG Matera - Pulmonary Therapy, 2019 - Springer
Guidelines are mainly based on evidence of well-designed randomized controlled trials
(RCTs), but there are limitations to the transferability of conclusions of RCTs to usual care …

Triple inhaler versus dual bronchodilator therapy in COPD: real-world effectiveness on mortality

S Suissa, S Dell'Aniello, P Ernst - COPD: Journal of Chronic …, 2022 - Taylor & Francis
Randomized trials of triple therapy including an inhaled corticosteroid (ICS) for chronic
obstructive pulmonary disease (COPD) reported remarkable benefits on mortality compared …

[HTML][HTML] Triple inhaled therapy in COPD patients: determinants of prescription in primary care

DL Vetrano, A Zucchelli, E Bianchini, C Cricelli… - Respiratory …, 2019 - Elsevier
Objective To assess the incidence and determinants of the triple inhaled therapy in chronic
obstructive pulmonary disease (COPD) primary care patients. Methods Data derived from …

Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta …

Y Oba, E Keeney, N Ghatehorde… - Cochrane Database of …, 2018 - cochranelibrary.com
Background Long‐acting bronchodilators such as long‐acting β‐agonist (LABA), long‐
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …

The impact of 52-week single inhaler device triple therapy versus dual therapy on the mortality of COPD patients: a systematic review and meta-analysis of …

CC Lai, CH Chen, KH Chen, CY Wang, TM Huang… - Life, 2022 - mdpi.com
There are more single inhaler device triple therapy available for COPD patients now.
However, the effect of long-term triple therapy fixed dose combination (FDC) on mortality …